NCT02126761已完成1 期
A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage-Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
Seqirus2 个研究点 分布在 1 个国家目标入组 196 人开始时间: 2014年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 196
- 试验地点
- 2
- 主要终点
- Seroconversion/significant increase in antibody HI titers; ≥4-fold rise in MN titer 21 days post-vaccination.
研究概览
简要总结
In this study, the safety and immunogenicity of the current formulation of aTIV will be compared to aTIV-modified formulations in which the dosage of the MF59 adjuvant will be doubled or tripled and/or the dosage of the 3 influenza virus strains will be doubled, in independently-living elderly subjects ≥ 65 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects ≥65 years of age on the day of screening who are healthy or have chronic illnesses that are stable and well controlled.
- •Subjects assessed as mentally competent, who have given informed consent after the nature of the study has been explained according to local requirements
- •In good health as determined by:
- •Ability to live independently
- •Medical history
- •Physical examination
- •Clinical judgment of the Investigator
- •Able to understand and comply with all study procedures and visits, and are able to complete an eDiary
- •Individuals who have access to a working telephone and are able to receive periodic telephone calls
排除标准
- •Individuals who have received any type of influenza vaccine (licensed or experimental) within the past 6 months
- •Individuals who have received any other licensed vaccines within 30 days (for inactivated vaccines) or 42 days (for live vaccines) prior to enrollment in this study
- •Individuals who have cancer except for:
- •Benign localized skin cancer
- •Localized prostate cancer that has been clinically stable for ≥ 2 years without treatment
- •Cancer in remission for ≥ 10 years (from end of cancer treatment)
- •Individuals with autoimmune disease (including rheumatoid arthritis)
- •Individuals with diabetes mellitus, type I
- •Individuals with a body mass index (BMI) ≤18 or ≥
- •Asthma that is greater than mild in severity and / or has exacerbations more than 2 days per week
- •Congestive heart failure with symptoms as severe as or more severe than dyspnea with short walks or climbing a single flight of stairs (for example, greater than New York Heart Association class 2)
- •History of progressive or severe neurologic disorders including but not limited to multiple sclerosis, Parkinson's disease, Guillain-Barré syndrome, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, epilepsy disorders requiring medication for control, encephalitis, Alzheimer's and CVA
- •Individuals who are hypersensitive to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulfate or any other component of the vaccines in study
- •Individuals who have a history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine
- •Individuals who have a known or suspected (or have a high risk of developing) impairment/alteration of immune function resulting from, for example,
- •a. Receipt of immunosuppressive therapy (defined as follows) within the past 60 days and/or anticipated to receive immunosuppressive therapy at any point within 21 days of Visit
- •i. Cancer chemotherapy/radiotherapy ii. Systemic corticosteroids ( i.e., 15 mg or greater per day of prednisone or equivalent) iii. Chronic use of inhaled/intranasal high potency corticosteroids (budesonide 800 μg per day or fluticasone 750 μg per day) b. Receipt of immunostimulants c. Receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivate within the past 3 months and for the full length of the study d. Suspected or known HIV infection or HIV-related disease
- •Individuals who have a known or suspected history of drug or alcohol abuse
- •Individuals who, within the past 12 months, have had laboratory confirmed influenza disease
- •Individuals who, within the past 30 days have received any investigational agent.
- •Individuals who plan to receive another vaccine within 30 days of receipt of the study vaccination.
- •Individuals who, within the past 14 days, have experienced:
- •Any acute disease including any worsening of underlying respiratory diseases such as asthma or COPD
- •Infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable)
- •Individuals who are taking part in another clinical study
- •Individuals who are research staff directly involved with the clinical study or family members or household members of research staff. Research staff includes an individual with direct or indirect contact with study subjects, or study site personnel who have access to any study documents containing subject information. This would include receptionists, persons scheduling appointments or making screening calls, regulatory specialists, laboratory technicians, etc.
- •Individuals with behavioral or cognitive impairment or a psychiatric condition that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- •Vulnerable subjects, e.g. subjects kept in detention, soldiers, employees of the sponsor or a clinical research organization involved in this study
- •Individuals who have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
结局指标
主要结局
Seroconversion/significant increase in antibody HI titers; ≥4-fold rise in MN titer 21 days post-vaccination.
时间窗: Day 22 post-vaccination
Antibody responses to all three influenza virus vaccine strains, 21days after a dose or doses of aTIV or aTIV-modified formulations, as measured by hemagglutination inhibition (HI) assay and microneutralization (MN) assay.
Reactogenicity up to 7 days after vaccination
时间窗: Days 1-7 post-vaccination
Safety of aTIV or aTIV-modified formulations
SAEs, non-scheduled physician visits, unsolicited medically attended AEs, unsolicited AEs leading to study withdrawal, NOCDs, and AESIs from study start to study completion.
时间窗: Days 1-366 post-vaccination
Unsolicited AEs within 28 days after vaccination
时间窗: Days 1-28 post-vaccination
HI and MN GMT and GMR at baseline and 21 days post-vaccination.
时间窗: Day 1; Day 22 post-vaccination
次要结局
- Percentage of subjects with HI titers ≥1:40, ≥1:110, ≥1:160, and ≥1:330 7 days, 21 days, and 6 months post-vaccination.(Day 8, 22, and 181 post-vaccination)
- HI and MN (GMT) 7 days and 6 months post-vaccination.(Day 8 and 181 post-vaccination)
- HI and MN (GMR) 7 days, 21 days, and 6 months post-vaccination.(Day 1, 8, 22, and 181 post-vaccination)
- Seroconversion/significant increase in antibody HI titers; ≥4-fold rise in MN titer, 7 days and 6 months post-vaccination.(Day 8 and 181 post-vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in AdultsCOVID-19NCT05228314Clover Biopharmaceuticals AUS Pty Ltd153
已完成
4 期
A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy VolunteersInfluenza, HumanNCT01591837Seqirus120
已完成
4 期
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersInfluenza, HumanNCT01857297Seqirus120
已完成
2 期
Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B VaccineHepatitis BNCT00805389GlaxoSmithKline713
终止
1 期
A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)HIV InfectionNCT01441193Barbara Ensoli, MD11